Edith A. Perez

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Retrieved on: 
Friday, November 3, 2023
FDA, Research, Regenerative Medicine Advanced Therapy, Food, Spinal muscular atrophy, Biogen, SCD, Life, Public expenditure, TDT, Cas9, Sickle cell disease, Regulation of tobacco by the U.S. Food and Drug Administration, Poster, Society, ASH, Commercialization, HSC, File, Fetal hemoglobin, Collaboration, Lead, Beta thalassemia, Anemia, Multiple sclerosis, Bone marrow, Therapy, Patient, BLA, MS, Pharmaceutical industry, Cryptocurrency, Edith A. Perez, Editas Medicine, EU

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.
  • Cash, cash equivalents, and marketable securities as of September 30, 2023, were $446.4 million compared to $480.0 million as of June 30, 2023.
  • The increase is primarily related to an upfront payment for the non-exclusive Cas9 license to Vor Bio in the third quarter of 2023.
  • Editas Medicine plans to participate in the following scientific and medical conference:
    Editas Medicine plans to participate in the following investor events:

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Retrieved on: 
Thursday, November 2, 2023
Trial of the century, OH, Event, Safety, Sickle cell disease, Society, ASH, Senior, American Society of Pediatric Hematology/Oncology, Caregiver, Fetal hemoglobin, Editas Medicine, Patient, Blood, Pharmaceutical industry, Nursing, Blood product, Edith A. Perez

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online.

Key Points: 
  • Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m.
  • Editas Medicine will also host a Company-sponsored webinar on Monday, December 11, at 1:00 p.m.
  • ET to discuss the RUBY and EdiTHAL clinical data.
  • Clinical data on six patients, including at least five months data from the first two patients treated.

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

Retrieved on: 
Thursday, July 27, 2023
Acceleration, GMP, Edith A. Perez, Partnership, Editas Medicine, Azur, Senior, SCD, Science, COD, Sickle cell disease, TDT, Greater Boston, Pharmaceutical industry, Operation

The expanded agreement includes compliant cleanroom space and labs services at Azzur's COD site in Devens, Massachusetts.

Key Points: 
  • The expanded agreement includes compliant cleanroom space and labs services at Azzur's COD site in Devens, Massachusetts.
  • Editas Medicine has utilized Azzur's services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 for the treatment of sickle cell disease and beta thalassemia, since 2020 .
  • Azzur Group recently celebrated the groundbreaking of the Devens site , which is its third COD facility in the Greater Boston Area.
  • "As our partnership has grown, Azzur has continued to support us and our evolving needs to manufacture clinical supply to support the advancement of our RUBY trial and EdiTHAL trial of EDIT-301.

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

Retrieved on: 
Thursday, July 27, 2023
Acceleration, GMP, Edith A. Perez, Partnership, Editas Medicine, Azur, Senior, SCD, Science, COD, Sickle cell disease, TDT, Greater Boston, Pharmaceutical industry, Operation

The expanded agreement includes compliant cleanroom space and labs services at Azzur’s COD site in Devens, Massachusetts.

Key Points: 
  • The expanded agreement includes compliant cleanroom space and labs services at Azzur’s COD site in Devens, Massachusetts.
  • Editas Medicine has utilized Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 for the treatment of sickle cell disease and beta thalassemia, since 2020 .
  • Azzur Group recently celebrated the groundbreaking of the Devens site , which is its third COD facility in the Greater Boston Area.
  • “As our partnership has grown, Azzur has continued to support us and our evolving needs to manufacture clinical supply to support the advancement of our RUBY trial and EdiTHAL trial of EDIT-301.

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

Retrieved on: 
Friday, June 9, 2023
Male, HBF, Blood, Senior, European Hematology Association, Life, Event, OH, Gene editing, SCD, Clinical trial, Aes, RAF Sullom Voe, Female, EDT, Editas Medicine, Șaeș, American Society of Pediatric Hematology/Oncology, Fetal hemoglobin, MD, Patient, Anemia, Busulfan, EHA, Sickle cell disease, Safety, Pharmaceutical industry, Nursing, Edith A. Perez

ET

Key Points: 
  • ET
    Company to host a virtual event on the RUBY and EdiTHAL data on Monday, June 12 at 8:00 a.m.
  • Editas Medicine will present the RUBY trial data and the EdiTHAL trial data on Monday, June 12, at 8 a.m.
  • All four treated patients in the RUBY trial are free from vaso-occlusive events since infusion with EDIT-301, with 2-10 months follow-up.
  • EDIT-301 is currently being investigated in clinical studies in patients with severe sickle cell disease (RUBY trial, NCT04853576) and transfusion-dependent beta thalassemia (EDITHAL trial, NCT05444894).

Society to Improve Diagnosis in Medicine (SIDM) Announces Appointments of New Board Members

Retrieved on: 
Wednesday, May 3, 2023
Cornell University, Bachelor, University, Frana Cardno, Partnership, Senior, Military, Marketing, AARP, Consultant, Wabash College, Policy, Senior advisor, Chapel Hill, Woman, Mentorship, Doctor of Philosophy, Uttar Pradesh State Board of High School and Intermediate Education, Social marketing, Central Waqf Council, National Board of Medical Examiners, National Executive Board of the Boy Scouts of America, Edith A. Perez, Institutional Limited Partners Association, NBME, SIDM, Growth, Samuel Curtis Johnson Graduate School of Management, Fortune 500, Diagnosis, Medical device, Management, Epidemiology, New York University, Medicine

ALPHARETTA, Ga., May 3, 2023 /PRNewswire/ -- Society to Improve Diagnosis in Medicine (SIDM) is pleased to announce the appointment of Helene Epstein, Dr. Kenneth A. Mundt, Kamili Wilson, and Von Wright to its Board of Directors.

Key Points: 
  • ALPHARETTA, Ga., May 3, 2023 /PRNewswire/ -- Society to Improve Diagnosis in Medicine (SIDM) is pleased to announce the appointment of Helene Epstein, Dr. Kenneth A. Mundt, Kamili Wilson, and Von Wright to its Board of Directors.
  • She has served on committees, panels, and various boards for medical research projects, healthcare organizations, public schools, and grant-givers.
  • Ms. Wilson is also a former executive board member for the Arlington Retirement Housing Corporation (ARHC) and a former member of DoSomething.org's Corporate Advisory Board.
  • "We are thrilled to welcome these highly accomplished individuals to our Board of Directors," said CEO Jennie Ward-Robinson, PhD.

New Treatment Authorized and Available for Canadians with HER2+ Breast Cancer

Retrieved on: 
Tuesday, July 20, 2021
Clinical medicine, Health, Drugs, Antineoplastic drugs, Breast cancer, Trastuzumab, Pertuzumab, Metastatic breast cancer, Cancer, Breast cancer management, Edith A. Perez

As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive.

Key Points: 
  • As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive.
  • The Right Treatment for the Right Patient Personalised Treatment of Breast Cancer.
  • Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis.
  • The Right Treatment for the Right Patient Personalised Treatment of Breast Cancer.